Organon's revenue decline persists, with 2026Q2 sales down 2.3% YoY, reflecting China VBP and biosimilar pricing pressures. However, the company maintains a stable cash flow profile, with operating cash flow of $107M in 2026Q2 and cumulative OCF exceeding net ...
Price trend, volume and key moving averages
Trailing total returns as of 10/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 31, 2026 | $0.85+0.0% vs $0.85 | $1.6B+0.0% vs $1.6B |
Q2 2026 Apr 30, 2026 | $0.71-14.5% vs $0.83 | $1.5B-1.9% vs $1.5B |
Q1 2026 Feb 12, 2026 | $0.63-13.7% vs $0.73 | $1.5B-1.8% vs $1.5B |
Q4 2025 Nov 10, 2025 | $1.01+8.6% vs $0.93 | $1.6B+5.3% vs $1.5B |
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to unveil first large-scale real-world effectiveness analyses of VTAMA (tapinarof) cream, 1% in patients with eczema at Fall Clinical.
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Organon and Co. (NYSE: OGN) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 56,850 shares of the company's stock, valued at approximately $770,000. A number of other hedge funds and other institutional investors
Benchmark OGN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Organon & Co. (OGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.74 | $3.61B | 19.08 | -2.92% | 3.01% | 30.56% | 2.46% | |
| $27.49 | $156.65B | 20.21 | -1.65% | 6.81% | 4.87% | — | |
| $17.54 | $20.43B | -5.85 | -2.98% | -2.79% | -2.79% | — | |
| $266.79 | $471.37B | 112.57 | 8.57% | 9.81% | — | — | |
| $8.87 | $39.56B | 18.56 | -1.81% | 14.18% | 19.35% | — | |
| $39.13 | $46.21B | 32.61 | 4.31% | 4.08% | 9.06% | — |
Organon & Co. (OGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Organon & Co. (OGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 31, 2026·SEC
Jul 23, 2026·SEC
Jul 17, 2026·SEC
Get notified when OGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Organon & Co. (OGN) stock FAQ — growth, dividends, profitability & financials explained
Organon & Co. (OGN) reported $6.13B in revenue for fiscal year 2025. This represents a 37% decrease from $9.78B in 2018.
Organon & Co. (OGN) saw revenue decline by 2.9% over the past year.
Yes, Organon & Co. (OGN) is profitable, generating $209.0M in net income for fiscal year 2025 (3.0% net margin).
Yes, Organon & Co. (OGN) pays a dividend with a yield of 2.46%. This makes it attractive for income-focused investors.
Organon & Co. (OGN) has a return on equity (ROE) of 30.6%. This is excellent, indicating efficient use of shareholder capital.
Organon & Co. (OGN) generated $498.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
